International Journal of Drug Regulatory Affairs
  • Year: 2024
  • Volume: 12
  • Issue: 3

Regulatory Development, Adoption, and Perseverance of Real-world Evidence with global health authorities

  • Author:
  • Sanyam Gandhi1,*, Kinshuk Saxena2, C Kartikeyan3, Akhilesh Tiwari4, Sachin Jain5, Vikas Jain6, Pradeep Pal7
  • Total Page Count: 11
  • Page Number: 44 to 54

1Takeda Pharmaceutical Company Limited, 300 Massachusetts Ave, Cambridge, MA, 02139, USA

2Lead - Commercialization Strategy and Operations, Novartis, New Jersey, USA

3Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh, 484887, India

4Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh, 484887, India

5Oriental College of Pharmacy & Research, Oriental University, Indore, 453555, Madhya Pradesh, India

6Principal, Mahakal Institute of Pharmaceutical Studies, Ujjain, Madhya Pradesh, 456664, India

7Associate Professor, Mahakal Institute of Pharmaceutical Studies, Ujjain, Madhya Pradesh, 456664, India

*Corresponding author

Online Published on 01 July, 2025.

Abstract

Real-world evidence (RWE) has gained significant attention as a valuable source of evidence in healthcare decision-making. This article provides a comprehensive analysis of the regulatory development, adoption, and perseverance of RWE with global health authorities, as well as a synopsis of the major trends and practices among global health authorities. The aim is to shed light on the current landscape, and prospects of utilizing RWE in regulatory processes. Globally, many health authorities are drafting guidelines for RWE and implementing various regulations. Implementation is in the initial stages because RWE has certain limitations. This article examines the experiences of selected global health authorities in the development and implementation of RWE strategies. It also examines regulatory guidelines, pilot programmes, and collaborations designed to establish a solid foundation for the use of RWE. However, despite all challenges and limitations, RWE is widely being used in drug approval and commercial sense.

Keywords

Real-world evidence (RWE), Clinical Trials, Randomized controlled trials (RCTs), FDA, CBER, PMDA, TMDA, ICH, Covid-19, Health Canada